Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study

Table 1

Baseline characteristics of patients.

Characteristic	Group 1	Group 2	value
Number	19	20	0.127
Gender (F/M)	4/15	5/15	0.770
Age (years)	42.1 ± 7.6	42.3 ± 9.9	0.127
Family history (with/without)	10/9	10/10	0.869
Blood pressure (mmHg)
Systolic	116.5 ± 12.3	118.2 ± 11.7	0.914
Diastolic	74.4 ± 9.9	77.4 ± 12.0	0.372
Weight (kg)	71.6 ± 8.7	71.0 ± 8.2	0.441
BMI (kg/m^2)	25.5 ± 2.4	25.4 ± 2.8	0.743
Waist circumference (cm)	89.0 ± 6.9	89.4 ± 7.9	0.869
Waist to hip ratio	1.07 ± 0.62	0.94 ± 0.07	0.088
HbA1c (%)	10.2 ± 2.0	10.0 ± 2.1	0.862
FPG (mmol/L)	10.5 ± 3.3	10.4 ± 2.6	0.130
PPG (mmol/L)	15.2 ± 6.1	14.4 ± 4.1	0.025
Triglyceride (mmol/L)	1.80 (1.50)	1.43 (1.69)	0.899
CHOL (mmol/L)	5.1 ± 0.9	5.2 ± 1.1	0.408
LDL-c (mmol/L)	3.33 ± 0.83	3.52 ± 0.71	0.461
HDL-c (mmol/L)	1.18 ± 0.46	1.09 ± 0.19	0.099
AIR (μU⋅min/mL)	−6.60 (26.2)	−6.98 (21.71)	0.911
HOMA-IR	2.57 (2.78)	3.96 (2.71)	0.258
HOMA-B	20.48 (16.46)	20.16 (26.15)	0.584